Coinbase CEO criticizes U.S. Senate's crypto bill, highlighting potential setbacks for innovation.Coinbase CEO criticizes U.S. Senate's crypto bill, highlighting potential setbacks for innovation.

Coinbase CEO Opposes U.S. Crypto Bill Draft

What to Know:
  • Coinbase CEO challenges U.S. Senate crypto bill draft.
  • Brian Armstrong cites risks to innovation.
  • Potential impact on stablecoin yields and DeFi.

Coinbase CEO Brian Armstrong criticizes the cryptocurrency market structure bill by the U.S. Senate Banking Committee, arguing against its restrictive measures, on January 14, 2026.

Armstrong’s opposition highlights potential obstacles to U.S. crypto innovation, eliciting industry concern over regulatory impacts on DeFi and tokenized securities.

Coinbase CEO Brian Armstrong opposes the current U.S. Senate crypto bill, shared on X (formerly Twitter) on January 14, 2026, arguing it poses risks to innovation.

The bill’s controversial provisions could hinder decentralized finance and reduce stablecoin profitability, raising concerns across the cryptocurrency sector.

Armstrong Criticizes Senate Bill for DeFi Limitations

The U.S. Senate Banking Committee’s draft bill is under scrutiny. Brian Armstrong opposes it due to potential risks, including DeFi limitations and shifting regulatory authority away from the CFTC.

Key figures like Armstrong believe the bill will hinder technological progress. The proposed legislation restricts tokenized securities and stablecoin yields, impacting related revenue streams significantly.

Industry Concerns Over Proposed Crypto Regulations

The bill has drawn significant attention from industry players, impacting market sentiments. Critics argue the draft could negatively affect innovation in the digital currency ecosystem.

The proposed changes may lead to increased regulatory burden and a shift in oversight dynamics, affecting stablecoin revenues and broader regulatory frameworks for digital finance.

Past Legislation Shows Risks of Overregulation

Previous similar legislation faced challenges due to overreaching regulations. This draft echoes past issues with excessive regulatory proposals, previously stalling innovations and investments.

Potential outcomes include stricter controls on the crypto market. Historical trends suggest careful consideration is necessary to avoid hindering progress in digital asset management and usage.

Disclaimer: The information on this website is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency markets are volatile, and investing involves risk. Always do your own research and consult a financial advisor.
Market Opportunity
Union Logo
Union Price(U)
$0,00286
$0,00286$0,00286
-1,03%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26